CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) reinvigorate antitumor immune responses by targeting PD-1/PD-L1 pathways and show remarkable clinical efficacy in driver oncogene-negative NSCLC patients.